Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
: :
04, 2025 (GLOBE NEWSWIRE) -- Noom , the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, today announced the launch of the Noom Microdose GLP-1 Rx Program, a groundbreaking offering designed to unlock weight loss and long-term health benefits while minimizing side effects through personalized microdoses of GLP-1 medication, when clinically appropriate
Positive allosteric modulation of the glucagon-like peptide-1 receptor by diverse electrophiles
Editado por: Silvia Pellitero-Rodrguez - University Hospital Germans Trias i Pujol Badalona Federico Vzquez Sanmiguel - University Hospital Germans Trias i Pujol Badalona ltima actualizacin : Octubre 2025 Los frmacos con accin sobre el receptor del pptido similar al glucagn tipo 1 (GLP-1) son efectivos en el tratamiento de enfermedades metablicas asociadas a la obesidad, como la apnea obstructiva del sueo (AOS), la enfermedad heptica metablica (EHMET) y la enfermedad renal crnica (ERC)
Background technique [0002] Semaglutide, a long-acting GLP-1 analog developed by Nove Nordisk for subcutaneous injection once a week, was approved by the US FDA on December 5, 2017
